ArticleOncoimmunology

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

M Moehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.